Phase I study with toyocamycin (NSC-63701).
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D004285:Dogs; D006801:Humans; D007275:Injections, Intravenous; D009369:Neoplasms / Q000188:drug therapy*; D051381:Rats
D000903:Antibiotics, Antineoplastic